1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Changchun BCHT Biotechnology Co. Class A

Changchun BCHT Biotechnology Co. Class A

SSSE:688276
15.69
CNY
-0.74
(-4.50%)
-0.58EPS
5.77BMarket Cap
Oct 30Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.92
2.86
2.69
3.93
3.06
2.6
4.41
2.97
1.47
1.4
Basic EPS, GAAP
0.26
0.36
0.61
1.14
0.62
0.44
1.21
0.56
-0.64
-0.58
Free Cash Flow per Basic Share
0.24
0.25
0.29
-0.35
-1.25
-0.61
-0.52
-0.33
-0.43
- -
Dividend per Share
0.01
0.05
0.02
0.01
- -
0.1
0.15
0.16
0.18
0.19
Book Value per Share
4.62
6.1
7.79
4.79
8.28
8.62
9.74
10.2
9.31
9.17
Tangible Book Value per Share
3.77
5.14
6.12
3.8
7.36
7.7
8.9
9.4
8.36
8.23
Basic Weighted Avg Shares
360
356
362
367
393
413
414
414
410
397
Sales/Revenue/Turnover
691
1,019
976
1,441
1,202
1,071
1,825
1,229
605
558
Operating Margin (%)
24.04
16.26
28.77
33.21
28.69
22.54
34.71
24.47
-35.8
-35.34
Depreciation Expense
16
32
43
59
68
71
92
104
131
- -
Net Income, GAAP
93
128
221
418
244
182
501
232
-263
-231
Effective Tax Rate (%)
17.06
14.52
16.23
14.06
6.89
8.17
11.13
9.26
- -
- -
Profit Margin (%)
13.54
12.57
22.65
29.02
20.26
16.94
27.46
18.88
-43.4
-41.43
Working Capital
-20
20
146
542
1,441
1,341
1,230
1,048
318
304
LT Debt
- -
- -
- -
- -
- -
- -
- -
60
64
53
Total Equity
601
793
1,013
1,780
3,418
3,560
4,020
4,218
3,851
3,794
Return on Invested Capital (%)
- -
16.52
21.26
28.06
9.4
4.94
13.11
5.64
- -
- -
Return on Capital (%)
- -
17.46
21.34
28.51
9.38
5.2
13.2
5.58
- -
- -
Return on Common Equity (%)
- -
18.37
24.47
29.95
9.37
5.2
13.22
5.63
-6.51
-5.77

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
202
260
419
LT Borrowings
64
79
53
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
414
414
414
Market Capitalization
7,802
7,305
5,766

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,423
1,480
1,538
Cash, Cash Equivalents & STI
201
215
285
Accounts Receivable, Net
937
924
827
Inventories
227
274
338
Total Current Liabilities
1,105
1,155
1,234
Payables & Accruals
- -
- -
- -
ST Debt
202
260
419
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.06%
-8.7%
Free Cash Flow
- -
43.6%
28.96%
Net Income, GAAP
- -
-31.61%
-213.14%
Sales/Revenue/Turnover
- -
-8.11%
-50.77%
Total Cash Common Dividend
- -
2,487.23%
16.52%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
270
348
408
203
1,229
2025
162
123
- -
131
605
2026
147
157
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.19
0.26
-0.03
0.56
2025
- -
-0.18
- -
-0.25
-0.64
2026
-0.01
-0.12
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
- -
- -
0.16
2025
- -
0.17
- -
- -
0.18
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chun Lai Jiang
Full Time Employees
1,252
Sector
Health technology
Industry
Biotechnology
Address
1260 Huoju Road Changchun JI China 130103
IPO Date
Jun 25, 2021
Website
bchtpharm.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Changchun BCHT Biotechnology Co. Changchun BCHT Biotechnology Co. (688276.SS), founded in 2004 and headquartered at No. 138 Zhuoyue Street, Chaoyang District, Changchun, Jilin Province, China, operates as a biopharmaceutical company focused on the research, development, production, and commercialization of human vaccines for the prevention and treatment of infectious diseases, primarily serving the domestic Chinese market with international expansion efforts. Its approved product portfolio includes live attenuated varicella vaccine (chickenpox vaccine); human rabies vaccine (vero cell); freeze-dried live attenuated nasal influenza vaccine; and live attenuated herpes zoster vaccine (shingles vaccine), alongside a pipeline of vaccines in development and fully human monoclonal antibodies targeting infectious diseases. The company maintains state-of-the-art production facilities in Changchun High-tech Zone and employs approximately 1,270 personnel dedicated to innovative biomedical solutions. In recent developments, Changchun BCHT Biotechnology achieved the first export of its domestic shingles vaccine, signaling international market penetration; reported revenue of CNY 895.58 million on a trailing twelve-month basis with net income of CNY 20.92 million; and continues to advance its research pipeline, including ongoing promotion of the shingles vaccine amid substantial market penetration potential in China, where annual new cases exceed 1.5 million. Additionally, the company rejoined the Developing Countries Vaccine Manufacturers Network (DCVMN) in early 2025, strengthening global collaboration opportunities in vaccine access and development.